{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:40:49Z","timestamp":1784644849449,"version":"3.55.0"},"reference-count":41,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2017.1476","type":"journal-article","created":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T07:58:37Z","timestamp":1509609517000},"source":"Crossref","is-referenced-by-count":5,"title":["Neurological variability in chemotherapy\u2011induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review"],"prefix":"10.3892","author":[{"given":"Chen","family":"Makranz","sequence":"first","affiliation":[{"name":"Department of Oncology and Neurology, Leslie and Michael Gaffin Center for Neuro\u2011Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Khutsurauli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sharet Institute for Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Kalish","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sharet Institute for Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Eliahou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sharet Institute for Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Kadouri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sharet Institute for Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gomori","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sharet Institute for Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lossos","sequence":"additional","affiliation":[{"name":"Department of Oncology and Neurology, Leslie and Michael Gaffin Center for Neuro\u2011Oncology, Hadassah\u2011Hebrew University Medical Center, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,11,2]]},"reference":[{"key":"key20200713201621_b1-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/practneurol-2011-000010","article-title":"The posterior reversible encephalopathy syndrome: what's certain, what's new?","volume":"11","author":"Roth","year":"2011","journal-title":"Pract Neurol"},{"key":"key20200713201621_b2-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"key20200713201621_b3-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.STR.15.3.413","article-title":"Cerebral autoregulation","volume":"15","author":"Strandgaard","year":"1984","journal-title":"Stroke"},{"key":"key20200713201621_b4-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Ozcan","year":"2006","journal-title":"N Engl J Med"},{"key":"key20200713201621_b5-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","article-title":"Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer","volume":"63","author":"Allen","year":"2006","journal-title":"Arch Neurol"},{"key":"key20200713201621_b6-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1212\/01.wnl.0000264428.76387.87","article-title":"Sirolimus-induced posterior reversible encephalopathy","volume":"68","author":"Bodkin","year":"2007","journal-title":"Neurology"},{"key":"key20200713201621_b7-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1634\/theoncologist.12-11-1332","article-title":"Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature","volume":"12","author":"Rajasekhar","year":"2007","journal-title":"Oncologist"},{"key":"key20200713201621_b8-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1136\/jnnp.2007.121806","article-title":"Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma","volume":"78","author":"Junna","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20200713201621_b9-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1212\/01.wnl.0000269780.45472.16","article-title":"Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome","volume":"69","author":"Kozak","year":"2007","journal-title":"Neurology"},{"key":"key20200713201621_b10-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1445-5994.2004.00750.x","article-title":"Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed","volume":"35","author":"Stott","year":"2005","journal-title":"Intern Med J"},{"key":"key20200713201621_b11-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"key20200713201621_b12-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0887-8994(01)00265-X","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"24","author":"Kwon","year":"2001","journal-title":"Pediatric Neurology"},{"key":"key20200713201621_b13-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/0886022X.2015.1044400","article-title":"Clinical course, laboratory parameters and outcome of TTP pediatric patients presenting with posterior reversible encephalopathy syndrome","volume":"37","author":"Bhat","year":"2015","journal-title":"Renal failure"},{"key":"key20200713201621_b14-mco-0-0-1476","first-page":"1","article-title":"Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images","volume":"23","author":"Covarrubias","year":"2002","journal-title":"Am J Neuroradiol"},{"key":"key20200713201621_b15-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"key20200713201621_b16-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin-C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"key20200713201621_b17-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"American Journal of Hematology"},{"key":"key20200713201621_b18-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0272-6386(97)90042-1","article-title":"Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy","volume":"29","author":"Groff","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"key20200713201621_b19-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S0272-6386(04)00985-0","article-title":"The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin-C-induced hemolytic uremic syndrome","volume":"44","author":"Mistry","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key20200713201621_b20-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0730-725X(01)00217-X","article-title":"Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings","volume":"19","author":"Russell","year":"2001","journal-title":"Magn Reson Imaging"},{"key":"key20200713201621_b21-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/02841860410018494","article-title":"Severe neurotoxicity caused by gemcitabine treatment","volume":"43","author":"Larsen","year":"2004","journal-title":"Acta Oncol"},{"key":"key20200713201621_b22-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1200\/JCO.2006.08.4608","article-title":"Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43\u20139006","volume":"24","author":"Govindarajan","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20200713201621_b23-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/NRL.0000000000000105","article-title":"Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature","volume":"21","author":"How","year":"2016","journal-title":"The neurologist"},{"key":"key20200713201621_b24-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e5850","DOI":"10.1097\/MD.0000000000005850","article-title":"A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin","volume":"96","author":"Cherniawsky","year":"2017","journal-title":"Medicine"},{"key":"key20200713201621_b25-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ncpneuro1045","article-title":"Chemotherapy-related posterior reversible leukoencephalopathy syndrome","volume":"5","author":"Bhatt","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"key20200713201621_b26-mco-0-0-1476","first-page":"611","article-title":"Gemcitabine associated with posterior reversible encephalopathy syndrome (PRES): a case report and review of the literature","volume":"10","author":"Truong","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20200713201621_b27-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4103\/2279-042X.192464","article-title":"Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: A case report with review of literature","volume":"5","author":"Kabre","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"key20200713201621_b28-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J Clin Oncol"},{"key":"key20200713201621_b29-mco-0-0-1476","first-page":"415","article-title":"Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome","volume":"19","author":"Ito","year":"1998","journal-title":"Am J Neuroradiol"},{"key":"key20200713201621_b30-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/0140-6736(92)91826-T","article-title":"Neurological symptoms associated with cyclosporin plus doxorubicin","volume":"340","author":"Beck","year":"1992","journal-title":"Lancet"},{"key":"key20200713201621_b31-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e16.1","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20200713201621_b32-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20200713201621_b33-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","article-title":"Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution","volume":"84","author":"Muller","year":"2005","journal-title":"Ann Hematol"},{"key":"key20200713201621_b34-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20200713201621_b35-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"key20200713201621_b36-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2013","journal-title":"Br J Haematol"},{"key":"key20200713201621_b37-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.clcc.2016.09.004","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","volume":"16","author":"Turner","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"key20200713201621_b38-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report","volume":"37","author":"Rogier","year":"2016","journal-title":"Rev Med Interne"},{"key":"key20200713201621_b39-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","author":"Gore","year":"2009","journal-title":"J Clin Apher"},{"key":"key20200713201621_b40-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.51.5.1369","article-title":"Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI","volume":"51","author":"Ay","year":"1998","journal-title":"Neurology"},{"key":"key20200713201621_b41-mco-0-0-1476","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.3174\/ajnr.A4243","article-title":"Serum lactate dehydrogenase as a predictor of outcome in posterior reversible encephalopathy syndrome: imperative to unify","volume":"36","author":"Lv","year":"2015","journal-title":"Am J Neuroradiol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:16:27Z","timestamp":1594667787000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2017.1476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":41,"URL":"https:\/\/doi.org\/10.3892\/mco.2017.1476","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}